Status:
COMPLETED
SSC-COVID in Patients After COVID-19
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Secondary Sclerosing Cholangitis
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic
Detailed Description
In Central Europe, the first wave of SARS-CoV-2 peaked in April 2020 and ended in June 2020. Our tertiary care center, the University Hospital of Tübingen is located in a first-wave SARS-CoV-2 hotspot...
Eligibility Criteria
Inclusion
- post-COVID19-patients with required hospitalization during the first wave of COVID-19-pandemic
- patients controlled at the university ambulance for follow-up
Exclusion
- children and patients younger than 18 years
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT05233553
Start Date
March 1 2020
End Date
January 31 2022
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Tuebingen
Tübingen, Germany, 72076